Business
Half-year Financial Report
Abingdon Health plc reported a 45% increase in total revenue to £4.5 million for the six months ended December 31, 2025, with reported revenue reaching £4.2 million. The company expects the second half of fiscal year 2026 to be profitable with positive operating cash flow, and maintains its full-year revenue guidance of £12.6 million. Despite an adjusted EBITDA loss of £1.7 million in the first half due to investment in growth, the company secured new contracts, including a $2.5 million deal announced on March 12, 2026, and is confident in its outlook for fiscal year 2027. Cash and cash equivalents stood at £3.7 million as of December 31, 2025, following a £3.2 million fundraising. Disclaimer*
About this update from Abingdon Health Plc
[{"type":"text","content":"\n\n\n \nAbingdon Health plc\n(\"Abingdon\" or \"the Company\" or \"the Group\")\n \nHalf-year Financial Report\n45% revenue growth, H2 to be profitable and cash flow positive, confident outlook for FY27\n \nYork, U.K. - 17 March 2026: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces its unaudited half-year Financial Report for the six months ended 31 December 2025 (\"H1 FY26\"). The Board expects H2 FY26 to deliver positive adjusted EBITDA and be operating cash flow positive.\n \nFinancial Summary\n· Total H1 FY26 revenues (including grant-funded income) up 45%* to £4.5 million (H1 FY25: £3.1 million).\n· Reported revenue of £4.2 million (H1 FY25: £3.1 million), representing growth of 37%.\n· Adjusted EBITDA** loss of £1.7 million (H1 FY25: £1.9 million) due to continued investment in the overhead base to support future growth and contract execution.\n· Loss before taxation of £2.3 million (H1 FY25: £2.6 million).\n· Successful placing and retail offer in October 2025 raising £3.2 million net of expenses, to accelerate US expansion and support execution of major contracts.\n· Cash and cash equivalents of £3.7 million at 31 December 2025 (30 June 2025: £1.9 million), following net placing proceeds of £3.2 million received in October 2025. H2 FY26 is expected to be EBITDA and operating cash flow positive.\n \nCommercial and Operational Highlights (including post-period end)\n· Continued strong growth in revenues driven by the Group's integrated, end-to-end CDMO and regulatory service offering.\n· Further expansion of US CDMO operations in Madison, Wisconsin with additional investment planned in H2 FY26 to support manufacturing fit-out, performance evaluation services and ISO accreditation.\n· Execution of several major ongoing CDMO contracts announced during calendar year 2025, including US $2m contract win with a new USA-based customer announced November 2025.\n· New $2.5m contract win announced 12 March 2026 to provide project management and expert technical support for the development and regulatory submission o...